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The beneficial effects of probiotics on immune-based pathologies such as inflammatory
bowel disease (IBD) have been well reported. However, their exact mechanisms have
not been fully elucidated. Few studies have focused on the impact of probiotics
on the composition of the colonic microbiota. The aim of the present study was
to correlate the intestinal anti-inflammatory activity of the probiotic Escherichia coli
Nissle 1917 (EcN) in the dextran sodium sulfate (DSS) model of mouse colitis with
the changes induced in colonic microbiota populations. EcN prevented the DSS-
induced colonic damage, as evidenced by lower disease activity index (DAI) values and
colonic weight/length ratio, when compared with untreated control mice. The beneficial
effects were confirmed biochemically, since the probiotic treatment improved the colonic
expression of different cytokines and proteins involved in epithelial integrity. In addition,
it restored the expression of different micro-RNAs (miR-143, miR-150, miR-155, miR-
223, and miR-375) involved in the inflammatory response that occurs in colitic mice.
Finally, the characterization of the colonic microbiota by pyrosequencing showed that
the probiotic administration was able to counteract the dysbiosis associated with the
intestinal inflammatory process. This effect was evidenced by an increase in bacterial
diversity in comparison with untreated colitic mice. The intestinal anti-inflammatory
effects of the probiotic EcN were associated with an amelioration of the altered
gut microbiome in mouse experimental colitis, especially when considering bacterial
diversity, which is reduced in these intestinal conditions. Moreover, this probiotic has
shown an ability to modulate expression levels of miRNAs and different mediators of the
immune response involved in gut inflammation. This modulation could also be of great
interest to understand the mechanism of action of this probiotic in the treatment of IBD.
Keywords: probiotic, microRNA, pyrosequencing, intestinal microbiota, DSS colitis
Abbreviations: CD, Crohn’s disease; CFU, colony-forming units; DAI, disease activity index; DSS, dextran sodium sulfate;
EcN, Escherichia coli Nissle 1917; emPCR, emulsion-based clonal amplification; F/B, Firmicutes/Bacteroidetes; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; IBD, inflammatory bowel disease; MAPKs, mitogen-activated protein kinases;
MG-RAST, metagenomics analysis server; miRNAs/mi-R, micro-RNAs; NF-κB, nuclear factor-κB; OCLN, occludin; PCR,
polymerase chain reaction; qPCR, real-time quantitative PCR; RDP, Ribosomal Database Project; RT, retrotranscription;
SCFAs, short-chain fatty acids; SNORD95, small nuclear RNA, C/D box 95; UC, ulcerative colitis; ZO, zonula occludens.
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INTRODUCTION
The gut microbiota is a very complex ecosystem that establishes a
symbiotic relationship with the host at the intestinal epithelium.
Although bacteria are considered the most prominent
component, gut microbiota also includes a few eukaryotic
fungi, viruses, and some Archaea (Power et al., 2014). Microbiota
composition changes along the axis of the human gastrointestinal
tract, and surface-adherent and luminal microbial populations
could differ from each other (Eckburg et al., 2005). This particular
bacterial composition is essential for maintaining the structural
integrity of the gut mucosal barrier, immunomodulation,
and nutrient and xenobiotic metabolism, among others’
effects. Moreover, the microbiota helps the host to distinguish
commensal organisms from episodic pathogens to orchestrate
the adequate responses (Patel and Lin, 2010). However, when
the composition of the microbiota is impaired (dysbiosis), this
symbiotic relationship does not function properly and the host
may identify the normal microbiota constituents as harmful,
which could trigger an inappropriate immune response. This
alteration could ultimately lead to inflammatory conditions such
as IBD. Different mediators, such as miRNAs, are involved in
the build-up of the inflammatory response in these conditions.
Some miRNAs have been described to participate in the control
of strategic cellular functions in the immune system, including
differentiation, proliferation, signal transduction, and apoptosis
(Xu and Zhang, 2016). Furthermore, miR-21, miR-122a, miR-
155, and miR-150 have been associated with impairment of tight
junction proteins and increased intestinal epithelial permeability
(Bian et al., 2011; Ye et al., 2011).
Therefore, the therapeutic approaches designed to modify
and restore the intestinal microbiota composition and the
inflammatory response could be of clinical relevance. Among
these treatments, the administration of probiotics, defined as “live
microorganisms, which, when consumed in adequate amounts,
confer a health benefit on the host” by an Expert Consultation
Committee at a meeting convened by the Food and Agriculture
Organization/World Health Organization in 2001, may play a
prominent role in the clinical management of these intestinal
conditions. Several mechanisms of action have been proposed
to explain their beneficial effects, including enhancement of the
epithelial barrier function, increased adhesion to the intestinal
mucosa, and concomitant inhibition of pathogen adhesion, as
well as competitive exclusion of pathogenic microorganisms
through production of antimicrobial substances and modulation
of the immune system (Prisciandaro et al., 2009). However, not
all microorganisms have the same efficacy in the treatment of
these conditions or display the same properties. These differences
are explained by their heterogeneity. In fact, only a few clinical
trials have been successful, despite a high number of studies
describing the efficacy of probiotics in experimental models
of colitis have been conducted (Ghouri et al., 2014). Human
trials have been performed either with bacterial mixtures, like
VSL#3, or with single probiotics, like Lactobacillus rhamnosus
GG, Saccharomyces boulardii, or EcN. Although the initial
trials showed benefits with all these probiotics, subsequent
studies or systematic reviews have questioned their efficacy,
reporting variations in probiotics effectiveness depending on
the form of IBD evaluated (UC, CD, or pouchitis) or the stage
(exacerbation or remission) of the intestinal conditions when
the probiotics were administered (Singh et al., 2015). In this
regard, when considering EcN, it was shown that despite the
administration of this probiotic in conjunction with standard
therapy to UC patients did not increase the induction rate of
remission, the treatment with this probiotic could have a similar
effect to mesalazine in maintaining the remission (Kruis et al.,
2004). In fact, since 2011, the “American Recommendations
for probiotic use” give very strong “A” recommendations for
the use of EcN for the maintenance of remission in human
UC (Floch et al., 2011). Several studies have reported immuno-
modulatory properties for EcN through different mechanisms
that could be responsible for its clinical efficacy in IBD. These
mechanisms are mainly associated with the ability of this
probiotic to modulate the cytokine production in immune cells
interfering with different cell pathways, including those involving
different transcription factors like NF-κB and modulating the
activity of the MAPKs (Grabig et al., 2006; Hafez et al., 2010).
Moreover, the antimicrobial properties of this probiotic, which
comprise both a direct effect and the stimulation of defensins
production by intestinal epithelial cells, can also contribute to
its beneficial effects in experimental colitis as well as in human
IBD (Wehkamp et al., 2004). However, despite numerous studies
have described the beneficial effects of different probiotics in
experimental colitis, they have not elucidated how probiotics
affect the microbiota composition in these conditions, where
the dysbiosis has been demonstrated. Therefore, the aim of the
present study was to investigate the effects of the administration
of EcN in an experimental model of colitis in mice, evaluating its
impact on the microbiota composition and correlating this to the
immuno-modulatory properties of this probiotic.
MATERIALS AND METHODS
Reagents and Probiotics
All chemicals were obtained from Sigma-Aldrich Quimica
(Madrid, Spain), unless otherwise stated. EcN was provided by
Ardeypharm GmbH (Herdecke, Germany).
Dextran Sodium Sulfate (DSS)-Induced
Colitis Mouse Model
The animals were housed in Makrolon cages, maintained in an
air-conditioned atmosphere with a 12 h light-dark cycle, and
provided with free access to tap water and food. All studies
were conducted according to the ‘Guide for the Care and
Use of Laboratory Animals’ as promulgated by the National
Institute of Health and the protocols approved by the “Animal
Experimentation Ethics Committee” of the University of Granada
(Spain; Ref. No. CEEA-2010-286).
Male C57BL/6J mice (7–9 weeks old; approximately 20 g)
obtained from Janvier (Saint-Berthevin Cedex, France) were
randomly assigned to three different groups of 10 animals each.
The non-colitic and the DSS-colitic groups received PBS solution
(200 µL), whereas the EcN group was daily treated with the
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FIGURE 1 | Effect of Escherichia coli Nissle 1917 (EcN) in DSS-induced colitis model. (A,B) Disease activity index (DAI) values and weight evolution in DSS-colitic
mice over the 26-day experimental period. Statistical significance among groups was evaluated by one-way ANOVA followed by Dunnett’s test. ∗p < 0.05 vs.
DSS-colitic group. (C) Colonic weight/length ratio, expressed as means ± SEM. Non-colitic group (n = 10), DSS-colitic (n = 10), and EcN (n = 10). Statistical
significance among groups was evaluated by one-way ANOVA followed by the Tukey’s test. Bars with different letters are significantly different (p < 0.05). Non-colitic:
untreated healthy group (n = 10); DSS-colitic: untreated DSS-induced colitic group (n = 10) and EcN: DSS-induced colitic group treated with probiotic (n = 10).
probiotic EcN at the concentration of 5 × 108 CFU, by using an
oesophageal catheter, for 26 days. Two weeks after the onset of the
study, colitis was induced in the DSS-colitic group and in the EcN
group by adding 3% DSS (36–50 kDa, MP Biomedicals, Ontario,
CA, United States) to drinking water for 6 days; subsequently,
DSS was removed (Mahler et al., 1998; Figure 1A). All the mice
were killed 26 days after the onset of the study with an overdose
of halothane.
Animal body weight, the presence of gross blood in the
feces, and the stool consistency were evaluated daily for each
mouse by a blind observer. A score was assigned to each
one of these parameters according to the criteria previously
proposed. These scores were used to calculate an average daily
of the DAI (Camuesco et al., 2004). Once the animals were
killed, the colon was removed aseptically, opened longitudinally,
and all the contents collected; then it was weighed, and its
length was measured under a constant load (2 g; Sanchez
de Medina et al., 1996). Representative specimens (0.5 cm
length containing all wall layers) were taken from the distal
inflamed region and fixed in 4% buffered formaldehyde
for histological analysis. The remaining colonic tissue and
the fecal content were immediately stored at –80◦C until
analysis.
Histological Studies
The formalin-fixed colonic specimens were paraffin-embedded,
sectioned (5 µm) at different levels and stained with alcian
blue and hematoxylin and eosin. The histological damage was
assessed by a blind observer according to a previous reported
histologic scoring system, which takes into account the presence
of ulceration, infiltration, edema, and the condition of the crypts
(Camuesco et al., 2012).
DNA Extraction and 454/Roche
Pyrosequence Analysis
A representative sample of each group (non-colitic, n = 3;
DSS-colitic, n = 4; and EcN, n = 3) was chosen to carry out
the microbiota analysis by pyrosequencing. Phenol:chloroform
(Sambrook and Russell, 2006) was used to isolate DNA from
fecal samples. Total DNA isolated from the stool samples was
amplified by PCR to compare the effect of different storage
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and purification methods on the recovery of 16S rRNA gene
sequence. Primers targeting regions flanking the variable regions
1–3 of the bacterial 16S rRNA gene (V1-3) were used. The
gel was purified and analyzed using the Roche 454 GS Junior
System (Roche Diagnostics, Branford, CT, United States). The
amplification of a 600-bp sequence in the variable region V1–V3
of the 16S rRNA gene was performed using bar-coded primers.
The PCR was performed in a total volume of 15 µL containing
the universal 27F and Bif16S-F forward primers (10 µmol
L−1) at a 9:1 ratio, and the bar-coded universal reverse primer
534R (10 µmol L−1), dNTP mix (10 mmol L−1), Fast Start
10 × buffer with 18 mmol L−1 of MgCl2, Fast Start HiFi
polymerase (5 U in 1 mL), and 2 µL of genomic DNA. The
dNTP mix, Fast Start 10 × buffer with MgCl2, and Fast Start
HiFi polymerase were included in a FastStart High Fidelity
PCR System, dNTP Pack (Roche Applied Science, Penzberg,
Germany). The PCR conditions were as follows: 95◦C for 2 min,
30 cycles of 95◦C for 20 s, 56◦C for 30 s, and 72◦C for
5 min, and a final step at 4◦C. After the PCR, amplicons were
further purified using AMPure XP beads (Beckman Coulter, Inc.,
Indianapolis, IN, United States) to remove smaller fragments.
The DNA concentration and quality were measured using a
Quant-iTTM PicoGreen R© dsDNA Assay Kit (Thermo Fisher
Scientific, Waltham, MA, United States). Finally, the PCR
amplicons were combined in equimolar ratios to create a DNA
pool (109 DNA molecules) that was used for emPCR and
pyrosequencing according to the manufacturer’s instructions
(Roche 454 GS Junior System; Roche Diagnostics, Branford, CT,
United States). Once the sequencing was completed, all reads
were scored for quality, and any poor quality and short reads were
removed.
Taxonomic Analysis
Sequences were selected to estimate the total bacterial diversity
of the DNA samples in a comparable manner and were trimmed
to remove barcodes, primers, chimeras, plasmids, mitochondrial
DNA, and any non-16S bacterial reads and sequences < 150 bp.
The MG-RAST (Meyer et al., 2008) with the RDP was used
for analyses of all sequences. The pipeline takes in bar-coded
sequence reads, separates them into individual communities by
bar code, and utilizes a suite of external programs to make
taxonomic assignments RDP database (Wang et al., 2007) and
estimates phylogenetic diversity, with a minimum e-value of 1e-
5, a minimum identity of 60%, and a minimum alignment length
of 15 measured in base pairs for RNA databases. Each value
obtained indicated the percentage of relative frequency of reads
with predicted proteins and ribosomal RNA genes annotated
to the indicated taxonomic level. The output file was further
analyzed using SPSS Statistics 17.0 Software Package (SPSS
Inc.) and Statistical Analysis of Metagenomic Profiles (STAMP)
software package version 2.1.3 (Parks et al., 2014).
Availability of Supporting Data
Metagenomic data sets for all samples are available on the
MG-RAST web server1, being sample IDs as follows: non-colitic,
1http://metagenomics.anl.gov/
4548801.3, 4548800.3, 4548793.3; DSS-colitic, 4548805.3,
4548804.3, 4548803.3, 4548802.3; and EcN, 4548806.3,
4548807.3, 4548784.3.
Analysis of Gene Expression in Mouse
Colonic Samples by RT-qPCR
Total RNA from colonic samples was isolated using the
RNeasy R© Mini Kit (Qiagen, Hilden, Germany) following the
manufacturer’s protocol. All RNA samples were quantified with
the Thermo Scientific NanoDropTM 2000 Spectrophotometer
(Thermo Fisher Scientific, Waltham, MA, United States) and
2 µg of RNA was reverse transcribed using oligo (dT) primers
(Promega, Southampton, United Kingdom).
Real-time quantitative PCR amplification and detection was
performed on optical-grade 48-well plates in an EcoTM Real-
Time PCR System (Illumina, CA, United States). Each reaction
contained 5 µL of KAPA SYBR R© FAST qPCR Master Mix
(Kappa Biosystems, Inc., Wilmington, MA, United States), each
amplification primer at a concentration of 10 µM, 20 ng of cDNA
from the RT reaction, and PCR-grade water up to a final volume
of 10 µL.
The thermal cycling program was as follows: an initial
denaturation step of 10 min at 95◦C, followed by 40 cycles
of 15 s at 95◦C and 1 min at annealing temperature (55–
62◦C). Fluorescence was measured at the end of the annealing
period of each cycle to monitor the progress of amplification,
and dissociation curves were added to confirm the specificity
of the amplification signal in each case. The expression of
the housekeeping gene, GAPDH, was measured to normalize
mRNA expression of target genes. For each sample, both the
housekeeping and the target genes were amplified in triplicate
and the mean value was used for further calculations. The mRNA
relative quantitation was done using the 11Ct method. Table 1
shows the primers used.
The miRNA from colonic samples was isolated after
homogenizing the tissue in QIAzolTM (Qiagen, Hilden,
Germany) using a Precellys R©24 homogenizer (Bertin
Technologies, Montigny-le-Bretonneux, France). Small RNA
(<200 nucleotides) fractions were isolated separately using the
miRNeasy mini Kit (Qiagen, Hilden, Germany) according to the
Supplementary Protocol provided by the manufacturer.
All miRNA samples were quantified with the Thermo
Scientific NanoDropTM 2000 Spectrophotometer (Thermo
Fisher Scientific, Waltham, MA, United States) and 500 ng of
miRNA was reverse transcribed using the miScript II RT kit from
Qiagen (Qiagen, Hilden, Germany).
Quantitative real-time PCR amplification and detection
was performed on optical-grade 48-well plates in an EcoTM
Real-Time PCR System (Illumina, CA, United States). Each
reaction contained 5 µL QuantiTect SYBR Green PCR Master
Mix (Qiagen, Hilden, Germany), 1 µL miScript Universal
Primer, 1 µL miScript Primer Assay, 2 ng of cDNA from
the RT reaction, and PCR-grade water up to a final volume
of 10 µL.
The thermal cycling program was as follows: an initial
activation step of 15 min at 95◦C, followed by 40 cycles
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TABLE 1 | Primer sequences used in real-time qPCR assays.


























with three-step cycling: 15 s at 94◦C for denaturation, the
annealing step at 55◦C for 30 s and 30 s at 70◦C for the
extension step. Fluorescence was measured at the extension
period of each cycle to monitor the progress of amplification,
and dissociation curves were added to confirm the specificity
of the amplification signal in each case. The expression of
the housekeeping gene, SNORD95, was measured to normalize
miRNA expression. For each sample, both the housekeeping
and target genes were amplified in triplicate and the mean was
used for further calculations. The miRNA relative quantitation
was done using the 11Ct method. Table 1 shows the primers
used.
Statistics
All statistical analyses were carried out with the GraphPad
Prism version 6.0 (GraphPad Software Inc., La Jolla, CA,
United States), with statistical significance set at p < 0.05.
DAI values and weight evolution in DSS-colitic mice were
analyzed using one-way analysis of variance (ANOVA) followed
by Dunnett’s test. Parametric comparisons were done using one-
way ANOVA followed by Tukey’s test. All variables are described
as mean± SEM.
RESULTS
In comparison with the non-treated group (non-colitic and DSS-
colitic), the administration of EcN to mice belonging to the EcN
group did not show any sign of toxicity, which was evaluated
by body weight increase, food intake, and general appearance
of the animals. The addition of 3% (w/v) of DSS to drinking
water for 6 days resulted in a progressive increase in DAI
values in the DSS-colitic group, due to body weight loss and
excretion of diarrheic/bleeding feces (Figure 1A). However, the
oral probiotic treatment attenuated the impact of the DSS damage
and boosted the recovery of the colitic mice (Figure 1B). These
effects were evidenced by a reduction in body weight loss and
by a lower incidence of diarrheic/bloody feces, which resulted
in significantly lower DAI values throughout the experiment
in the EcN group when compared to untreated colitic group
(0.8± 0.015 for EcN group vs. 1.72± 0.02 for DSS-colitic group;
Figure 1A). The macroscopic evaluation of the colonic segments
confirmed the beneficial effects found in probiotic-treated colitic
mice (EcN group), since they showed a significant reduction
in colonic weight/length ratio compared to the corresponding
DSS-colitic group (−23.7%, p < 0.05; Figure 1C). Of note,
it has been suggested that this ratio is directly correlated to
the severity of the colonic damage in this experimental model
of colitis (Arafa et al., 2009). Microscopically, the colonic
inflammation in the DSS-colitic group was characterized by an
intense ulceration affecting more than 75% of the surface and a
complete mucin depletion from goblet cells. In addition, severe
leukocyte infiltration and edema were frequently found in DSS-
colitic group. The damage was considered as very severe in most
of the sections, assigning a microscopic score (mean ± SEM)
of 30.0 ± 1.9 to the DSS-colitic group. The administration of
EcN improved the epithelial regeneration, showing a reduction
in the colonic ulcerated area, which was below 50% for all
samples, and preserved the goblet cells and their mucin content.
Moreover, the probiotic treatment decreased the inflammatory
cell infiltration and the edema in the mucosa, obtaining a
significant reduction in the microscopic score of the EcN group
(20.0 ± 2.5; p < 0.05) compared to the DSS-colitic group
(Figure 2).
The biochemical analysis of the colonic segments
corroborated the intestinal anti-inflammatory effect of this
probiotic, thus revealing its positive impact on the altered
colonic immune response induced by DSS intake. In this sense,
the probiotic significantly reduced the up-regulated expression
of the pro-inflammatory cytokines IL-1β and IL-12 found in
EcN group (−63.55% and −39.29%, p < 0.05, respectively;
Figure 3). The colonic inflammatory process was associated with
a 50% decrease of the TGF-β expression in EcN group compared
to the non-colitic group (p < 0.05). The TGF-β is a cytokine
that displays both anti-inflammatory and pro-inflammatory
properties, depending on the local cytokine milieu. However,
the probiotic treatment restored this cytokine expression to
values similar to non-colitic mice (Figure 3). EcN was also
able to significantly reduce by 38.58% the increased expression
of the adhesion molecule ICAM-1 found in DSS-colitic mice
(p < 0.05; Figure 3). As it has been previously described in
this experimental model of colitis (Garrido-Mesa et al., 2011,
2015), the colonic inflammation was associated with a reduced
expression of different proteins involved in the epithelial
integrity and barrier function of the colonic mucosa, like the
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FIGURE 2 | Escherichia coli Nissle 1917 (EcN) treatment promotes recovery
of DSS-induced intestinal injury and inflammation in mice. (A) Histological
images of colonic tissue stained with hematoxylin and eosin showing the effect
of EcN on DSS-induced colitis. Representative images of each experimental
group are shown: non-colitic, DSS-colitic, and EcN. In non-colitic mice, the
images show the normal appearance of the intact mucosa containing the
crypts with goblet cells full of mucin. In DSS-colitic group, the images show
changes in the mucosa with areas of ulceration on the epithelial layer, in
addition to a lower number of goblet cells which were depleted in mucin and
an intense inflammatory cell infiltrate. In EcN group, an improvement of the
colonic histology is found, with a reduced area of ulceration, mostly in process
of recovery, presence of goblet cells replenished with their mucin content and
reduced inflammatory cell infiltrate. (B) Histological scores calculated after
microscopic analyses of longitudinal colon sections. Results are expressed as
mean ± SEM. Statistical significance among groups was evaluated by
one-way ANOVA followed by the Tukey’s test. Different letters denote
significant differences between groups (p < 0.05). Non-colitic: untreated
healthy group (n = 10); DSS-colitic: untreated DSS-induced colitic group
(n = 10) and EcN: DSS-induced colitic group treated with probiotic (n = 10).
mucins MUC-3 and MUC-2, as well as OCLN and ZO-1.
The administration of this probiotic to colitic mice showed a
significant amelioration in the expression of all these markers
(Figure 4).
FIGURE 3 | Biochemical evaluation of the effects of Escherichia coli Nissle
1917 (EcN); mRNA expression of cytokines (A) IL-1β, (B) IL-12, (C) TGF-β,
and (D) ICAM-1 was quantified by real-time PCR, and fold changes are
expressed as means ± SEM. Non-colitic group (n = 10), DSS-colitic group
(n = 10), and EcN group (n = 10). Statistical analysis was performed with
one-way ANOVA followed by Tukey’s test. Bars with different letters are
significantly different (p < 0.05). Non-colitic: untreated healthy group (n = 10);
DSS-colitic: untreated DSS-induced colitic group (n = 10) and EcN:
DSS-induced colitic group treated with probiotic (n = 10).
The results obtained in this experimental model of DSS-
induced colitis confirmed that the intestinal inflammatory
process was associated with noticeable molecular changes in gene
expression. Also, these results support that the restoration of the
altered immune response is involved in the preventive beneficial
effects exerted by the probiotic assayed in experimental colitis.
Then, we explored if the expression of miRNAs, which have been
reported to play an important role in many biological processes,
such as signal transduction, cellular proliferation, differentiation,
apoptosis, and immune response (O’Connell et al., 2012), could
also be associated with the response to probiotic treatment. We
conducted a customized array of 80 different miRNAs chosen
based on an inflammatory panel found in the colonic tissue
of mice with DSS-induced colitis. In the present study, we
selected five of the eleven changed miRNA, specifically miR-
143, miR-150, miR-155, miR-223, and miR-375, and questioned
whether their expression was altered following treatment of
DSS-colitis mice with E. coli Nissle. The expressions of these
particular miRNAs were evaluated by qPCR. Results showed
that three of them, miR-150, miR-155, and miR-223, were
significantly upregulated (around twofold increase vs. healthy
control, p < 0.05) whereas the other two, miR-143 and miR-
375, were significantly downregulated in colitic mice compared
to non-colitic group (around twofold decrease, p < 0.05). The
treatment with the probiotic showed an amelioration of the
altered expression in some of the assessed miRNAs. Thus, EcN
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FIGURE 4 | Biochemical evaluation of the effects of Escherichia coli Nissle
1917 (EcN); mRNA expression of epithelial integrity proteins, (A) MUC-2, (B)
MUC-3, (C) occludin (OCLN), and (D) zonula occludens-1 (ZO-1), was
quantified by real-time PCR, and fold changes are expressed as
means ± SEM. Non-colitic group (n = 10), DSS-colitic group (n = 10), and
EcN group (n = 10). Statistical analysis was performed with one-way ANOVA
followed by Tukey’s test. Bars with different letters are significantly different
(p < 0.05). Non-colitic: untreated healthy group (n = 10); DSS-colitic:
untreated DSS-induced colitic group (n = 10) and EcN: DSS-induced colitic
group treated with probiotic (n = 10).
was able to significantly reduce the upregulated expressions of
miR-155 and miR-223 and downregulate miR-150 expression in
comparison with DSS-colitic mice (−37.7%, p < 0.05; Figure 5).
Moreover, the reduced expression of miR-143 in colitic mice was
also restored by the probiotic treatment (0.91 ± 0.06 in EcN
group vs. 1.00± 0.39 in DSS-colitic group, p > 0.05; Figure 5).
Subsequently, 16S ribosomal DNA sequencing and
bioinformatics alignment comparison against RDP database were
performed to study the modifications in the intestinal microbiota
composition in colitic mice after a DSS insult. The most
abundant phylum in the gut microbiota in the analyzed samples
was Firmicutes. However, significant differences in microbial
content were found among the different groups at the phylum
level (Figure 6A). The Firmicutes phylum was significantly
increased in the DSS-colitic group compared to non-colitic mice
(+86%, p < 0.05). The treatment with EcN was able to attenuate
this increase (p > 0.05 vs. healthy control; Figure 6A). Significant
reductions in Cyanobacteria and Bacteriodetes phyla were found
in the DSS-colitic group compared with non-colitic mice (−76.6
and −92.6%, respectively, p < 0.05). The probiotic treatment
used in the present study significantly increased Cyanobacteria,
and increased the proportion of sequences of Bacteriodetes up
to a value similar to that found in non-colitic mice (p > 0.05;
FIGURE 5 | Biochemical evaluation of the effects of Escherichia coli Nissle
1917 (EcN); the expression of (A) miR-150, (B) miR-155, (C) miR-223, (D)
miR-143, and (E) miR-375 was quantified by real-time PCR. Fold changes are
expressed as means ± SEM. Non-colitic group (n = 10), DSS-colitic group
(n = 10), and EcN group (n = 10). Statistical analysis was performed with
one-way ANOVA followed by Tukey’s test. Bars with different letters are
significantly different (p < 0.05). Non-colitic: untreated healthy group (n = 10);
DSS-colitic: untreated DSS-induced colitic group (n = 10) and EcN:
DSS-induced colitic group treated with probiotic (n = 10).
Figure 6A). Therefore, the F/B ratio was significantly increased
(13-fold) in the DSS-colitic group compared to the non-colitic
mice. This ratio, which has been used as a biomarker for different
pathological conditions including intestinal inflammation (Sanz
and Moya-Perez, 2014), was partially restored by EcN treatment
(Figure 6B). Based on the ordination plot of the distance matrix
generated using Bray–Curtis complementary algorithm, a clear
demarcation between bacterial assemblages from healthy and
DSS-colitic groups along principal coordinate axis 1 (PC1) of the
principal coordinate analysis (PCA) plot was found. The PCA
plot showed that the communities found in the probiotic-treated
colitic mice (EcN group) clearly differed from those in the
DSS-colitic group, but were quite similar to those found in the
non-colitic mice (p > 0.05; Figure 7A).
Additionally, significant changes in the proportion of
sequences of several bacterial genera were also found in
DSS-colitic mice compared to non-colitic group, including
Bifidobacterium, Bacillus, Cytophaga, Gardnerella, Lactobacillus,
Paenibacillus, Porphyromonas, and Synechocystis (Figure 7B).
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FIGURE 6 | Comparison of microbiota composition between non-colitic
group (n = 3), DSS-colitic group (n = 4), and Escherichia coli Nissle 1917
(EcN) group (n = 3). (A) Phylum breakdown of the most abundant bacterial
communities in the different groups. Results were expressed as the
mean ± SEM of the proportion of sequences and compared by one-way
ANOVA followed by Tukey’s test. (B) The Firmicutes/Bacteriodetes ratio (F/B
ratio) was calculated as a biomarker of gut dysbiosis. Statistical analysis was
performed with one-way ANOVA followed by Tukey’s test. Bars with different
letters are significantly different (p < 0.05).
The probiotic used in the present study was able to restore the
composition in all modified bacterial genera (Figure 7A).
Finally, several ecological features of the gut bacterial
communities were evaluated in the three experimental groups.
A variety of indices at the operational taxonomic unit (OTU) level
were determined. In particular, the compositions of bacterial
communities were characterized by calculating three major
ecological parameters, including Chao richness (an estimate
of a total community), Pielou evenness (showing how evenly
the individuals are distributed in the community over different
OTUs), and Shannon diversity (the combined parameter
of richness and evenness). Microbial richness, evenness,
and diversity were significantly decreased in the DSS-colitic
group compared to the non-colitic group. Importantly, the
administration of EcN to colitic mice was able to restore all these
ecological parameters to normal values (Figure 8).
DISCUSSION
Inflammatory bowel disease is characterized by an exacerbated
immune response that leads to chronic inflammation, associated
with drastic changes in gene and protein expression. This could
be partially ascribed to miRNAs, as they participate in many of
the signaling pathways involved. An imbalance in the intestinal
microbiota composition has been reported to contribute to the
pathogenesis of IBD (Kostic et al., 2014), and many studies focus
on the development of new strategies to restore it. They include
the administration of probiotics that exert beneficial effects in
human IBD and in experimental models of colitis (Grabig et al.,
2006; Garrido-Mesa et al., 2011). The present study corroborates
the intestinal anti-inflammatory effects of the probiotic, EcN,
which improved both macroscopic and biochemical parameters
in the DSS model of mouse colitis.
The administration of EcN enhanced the altered immune
response in colitic mice, thus confirming their intestinal
immuno-modulatory properties (Stephani et al., 2011).
Therefore, probiotic treatment restored the normal expression
of the pro-inflammatory cytokines IL-1β, TGF-β, and IL-
12. These cytokines are considered important inflammatory
mediators of innate and/or adaptive immunity, driving intestinal
inflammation (Korzenik and Podolsky, 2006). Similarly, other
inflammatory mediators, like chemokines or adhesion molecules,
are overexpressed in colitic mice Interestingly, EcN reduced
ICAM-1 expression, which could impair neutrophils and
macrophages access to intestinal inflamed areas. This effect has
been already reported, thus demonstrating a protective effect
against the acute inflammatory process (Souza et al., 2016).
Additionally, another initial event in intestinal inflammation is
the impairment of the epithelial barrier function (Mankertz and
Schulzke, 2007). Indeed, a defect in the mucus layer that covers
the epithelium and protects its integrity has been described in
human IBD (Gersemann et al., 2009) and in experimental models
of rodent colitis (McGuckin et al., 2009). In the present study,
DSS-induced colitis was also associated with a reduction in the
expression of mucins, MUC-2 and MUC-3, and tight junction
proteins, OCLN and ZO-1, which participate in maintaining
epithelial integrity (Kim and Ho, 2010). The probiotic used
in the present study significantly upregulated the expression
of the mucins as well as OCLN and ZO-1. This effect could
preserve the mucus-secreting layer and facilitate the restoration
of the epithelial barrier function and integrity, thus improving
intestinal permeability and promoting colonic recovery, in
consistency with previously described for probiotics (Persborn
and Soderholm, 2013). Regarding the study of the role of
miRNAs in the etiopathogenesis of intestinal inflammation and
the effect of EcN, we focused on five miRNAs, based on previous
studies in DSS-induced colitis (Rodriguez-Nogales et al., 2017).
Both miR-150 and miR-155 have been involved in the regulation
of the immune response by controlling the development and
function of innate immune cells. The expression of these
miRNAs is modulated by pro-/anti-inflammatory signals,
including cytokines, which in turn participate in the release of
other cytokines and chemokines (O’Connell et al., 2010, 2012).
Accordingly, the expression of both miR-150 and miR-155 has
been reported to be up-regulated in colonic epithelial cells in UC
patients and in colitic mice (Bian et al., 2011; Singh et al., 2014;
Lu et al., 2017). This upregulation has been confirmed in the
present study. However, EcN decreased the colonic expression of
both miRNAs, whereas it increased miR-150 expression, which
could facilitate colonic epithelial cell apoptosis via reduction
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FIGURE 7 | (A) Principal component analysis plot based on Bray–Curtis distances, calculated on the metagenomic table of fecal samples of the different groups
[non-colitic (n = 3), DSS-colitic (n = 4), and Escherichia coli Nissle 1917 (EcN; n = 3)]. (B) Mean percentage of sequences of the most important genera in
DSS-induced colitis model. Results were shown as the means ± SEM and compared by one-way ANOVA followed by Tukey’s test. Bars with different letters are
significantly different (p < 0.05).
of c-Myb (Bian et al., 2011). In fact, the decreased expression
of c-Myb found in DSS-induced colitis may promote epithelial
disruption and increase permeability of the gut. Therefore,
EcN could protect epithelial barrier integrity and restore the
altered immune response. The expression of miR-155 has been
reported to be upregulated in B and T lymphocytes, as well
as in macrophages, following antigen activation (O’Connell
et al., 2010). Moreover, miR-155−/− mice are protected
from DSS-induced colitis, likely through the reduction in the
upregulated Th1/Th17 responses that characterize DSS colitis
(Singh et al., 2014). Accordingly, the ability showed by EcN to
reduce the colonic expression of miR-155 in colitic mice could
account for its immuno-modulatory properties, also evidenced
by the downregulation of the pro-inflammatory cytokines
IL-1β and IL-12, in conjunction with the upregulation of the
anti-inflammatory cytokine TGF-β.
Similarly, an upregulation of miR-223 occurs in inflammatory
conditions; this miRNA is involved in the inflammosome
complex modulation and in IL-1β production (Haneklaus et al.,
2012). The probiotic administration in our study was able
to significantly reduce the expression of this miRNA and IL-
1β in colitic mice. Additionally, miR-143 seems to play an
important role in maintaining the normal colonic biology;
thus, when it downregulates the pro-inflammatory signals of
the innate immune system appear (Starczynowski et al., 2010).
Actually, the colonic expression of miR-143 was significantly
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FIGURE 8 | Estimation of the phylogenetic diversity of the gut microbiota
found in the different experimental groups; non-colitic (n = 3), DSS-colitic
(n = 4), and Escherichia coli Nissle 1917 (EcN; n = 3) using the (A) Chao
richness, (B) Shannon diversity, and (C) Pielou evenness. The values are
means, and error bars with different letters are significantly different (p < 0.05).
Statistical analysis was performed with one-way ANOVA followed by Tukey’s
test. Non-colitic: untreated healthy group (n = 3); DSS-colitic: untreated
DSS-induced colitic group (n = 4) and EcN: DSS-induced colitic group treated
with probiotic (n = 3).
downregulated in the DSS-colitic mice. However, EcN was
able to restore its colonic expression, thus preserving colonic
function and an adequate innate immune response. Finally,
miR-375 is considered a multifunctional miRNA, involved
in different processes including pancreatic islet development,
glucose homeostasis, or cell differentiation and carcinogenesis
(Xu et al., 2011); miR-375 displays different expression profiles
depending on the disease considered (Zhao et al., 2012). In
experimental colitis, a downregulation of miR-375 expression in
IL-10−/− mice once the signs of the colonic inflammation were
evident was reported (Schaefer et al., 2011). Similarly, in our
study, the expression of miR-375 was significantly reduced in
colitic mice in comparison with non-colitic ones. However, the
probiotic used by us failed to restore the basal levels of miR-375.
It is noteworthy that only few studies have evaluated the capacity
of probiotics to modulate miRNAs expression, and most of them
have been performed in vitro (Giahi et al., 2012). Therefore, these
results could show that the administration of the probiotic EcN
to colitic mice improve the altered immune response, maybe by
modifying miRNA expression in colonic tissue. Recently, host
miRNAs capable to specifically modulate gut microbiome have
been identified (DuPont and DuPont, 2011). In addition, it has
been suggested that probiotic administration reverses dysbiosis
and restores tolerance toward gut microbiota in these intestinal
conditions (DuPont and DuPont, 2011). Therefore, we suggest
that EcN, which can modulate different miRNAs’ expression,
could also restore the gut microbiota. This potential ability of this
probiotic has not been previously reported. Therefore, the present
study aims to characterize the different changes occurring in gut
microbiota by the action of this probiotic. First, three ecological
parameters were calculated, Chao richness, Pielou evenness,
and Shannon diversity, which were significantly reduced in the
DSS-colitic group when compared to the non-colitic group, as
previously reported in IBD patients (Frank et al., 2007; Walker
et al., 2011). Regarding the treatment, EcN restored the three
ecological parameters to healthy values. Moreover, the F/B ratio
increased in DSS-colitic mice compared to non-colitic mice; this
change in the ratio is associated with a significant expansion of
Firmicutes and a reduction of Bacteriodetes. EcN significantly
reduced F/B ratio in EcN group compared to DSS-colitic group.
These results seem inconsistent with some metagenomic studies
conducted in experimental models of intestinal inflammation and
in IBD patients which have previously reported a reduction in
the bacterial phylum Firmicutes (Frank et al., 2007; Atarashi and
Honda, 2011). However, other studies have described increased
levels of different subgroups of Firmicutes, including those that
include bacteria like Clostridium difficile, which seems to play a
key role in the pathogenesis of these conditions (Kim and Milner,
2007; Kim and Ho, 2010). Moreover, the ability showed by EcN to
produce an expansion of the Bacteriodetes phylum in colitic mice
can also contribute to its beneficial effects, since Bacteroidetes are
responsible for keeping the homeostasis in the gastrointestinal
tract (Kim and Milner, 2007). The bacterial populations that
produce SCFAs, like butyrate, propionate, and acetate, also
contribute to normal gut homeostasis. Although certain human-
derived butyrate-producing strain could aggravated colitis in
DSS-treated mice exerting no detrimental effect in healthy
mice, the SCFAs, and mainly butyrate, regulate epithelial cell
differentiation, barrier function, and stimulation of regulatory
T cells, being able to ameliorate mucosal inflammation in IBD
conditions (Hartog et al., 2015; Zhang et al., 2016). Interestingly,
butyrate main producer bacteria from the genera Bifidobacterium
and Lactobacillus (Manichanh et al., 2006) were reduced in DSS-
colitic mice, while both genera increased by EcN treatment.
Accordingly, the positive impact exerted by EcN on these
bacterial populations may also contribute to the beneficial
intestinal anti-inflammatory effects of this probiotic.
CONCLUSION
The present study demonstrates that the prophylactic
administration of the probiotic EcN displays an intestinal
anti-inflammatory effect in the experimental model of DSS-
induced acute colitis in mice, in consistency with previous
studies (Schultz et al., 2004; Garrido-Mesa et al., 2011). The
mechanisms involved could be associated with the immuno-
modulatory capacity of EcN. Regarding the latter, this probiotic
treatment shows a positive impact on the innate immune
response, preserving intestinal barrier integrity and decreasing
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pro-inflammatory cytokines production. Concerning the
adaptive immune response, EcN modulates the expression of
Th1-, Th17- and Treg-related cytokines. These actions could
be achieved at a post-transcriptional level by modifying the
expression of some miRNAs altered in inflammatory conditions.
The restoration of miRNAs expression by EcN pre-treatment
was associated with its ability to ameliorate the gut dysfunction
by improving microbial homeostasis, compromised after DSS
administration. This is the first study that describes the
mechanism of action of EcN through miRNAs this mechanism
in the DSS model of experimental colitis, since many studies
have demonstrated the ability of probiotics to improve dysbiosis,
but just a few studies have linked probiotics to their capacity
to modulate miRNAs expression and different mediators of the
immune response involved in gut inflammation. This could be
of great interest to understand the mechanism of action of this
probiotic in the treatment of IBD.
DATA AVAILABILITY
Data can be requested from the corresponding author.
AUTHOR CONTRIBUTIONS
AR-N, FA, JG-M, MU, TV, and MR-C performed the experiments
and contributed to the acquisition and analysis of data. AR-N,
NC, JF-C, and FG contributed to the taxonomic analysis and
data interpretation. AR-N, FA, MU, MR-C, and JG designed the
experiments and wrote the manuscript.
FUNDING
This work was supported by the Junta de Andalucía (CTS 164)
and by the Spanish Ministry of Economy and Competitiveness
(SAF2011-29648 and AGL2015-67995-C3-3-R) with funds from
the European Union. The funders had no role in the study design,
data collection, and analysis.
ACKNOWLEDGMENTS
We acknowledge Nutraceutical Translations for English language
editing of this manuscript.
REFERENCES
Arafa, H. M., Hemeida, R. A., El-Bahrawy, A. I., and Hamada, F. M.
(2009). Prophylactic role of curcumin in dextran sulfate sodium (DSS)-
induced ulcerative colitis murine model. Food Chem. Toxicol. 47, 1311–1317.
doi: 10.1016/j.fct.2009.03.003
Atarashi, K., and Honda, K. (2011). Microbiota in autoimmunity and tolerance.
Curr. Opin. Immunol. 23, 761–768. doi: 10.1016/j.coi.2011.11.002
Bian, Z., Li, L., Cui, J., Zhang, H., Liu, Y., Zhang, C. Y., et al. (2011). Role
of miR-150-targeting c-Myb in colonic epithelial disruption during dextran
sulphate sodium-induced murine experimental colitis and human ulcerative
colitis. J. Pathol. 225, 544–553. doi: 10.1002/path.2907
Camuesco, D., Comalada, M., Rodriguez-Cabezas, M. E., Nieto, A., Lorente, M. D.,
Concha, A., et al. (2004). The intestinal anti-inflammatory effect of quercitrin
is associated with an inhibition in iNOS expression. Br. J. Pharmacol. 143,
908–918. doi: 10.1038/sj.bjp.0705941
Camuesco, D., Rodriguez-Cabezas, M. E., Garrido-Mesa, N., Cueto-Sola, M.,
Bailon, E., Comalada, M., et al. (2012). The intestinal anti-inflammatory effect
of dersalazine sodium is related to a down-regulation in IL-17 production
in experimental models of rodent colitis. Br. J. Pharmacol. 165, 729–740.
doi: 10.1111/j.1476-5381.2011.01598.x
DuPont, A. W., and DuPont, H. L. (2011). The intestinal microbiota and chronic
disorders of the gut. Nat. Rev. Gastroenterol. Hepatol. 8, 523–531. doi: 10.1038/
nrgastro.2011.133
Eckburg, P. B., Bik, E. M., Bernstein, C. N., Purdom, E., Dethlefsen, L., Sargent, M.,
et al. (2005). Diversity of the human intestinal microbial flora. Science 308,
1635–1638. doi: 10.1126/science.1110591
Floch, M. H., Walker, W. A., Madsen, K., Sanders, M. E., Macfarlane, G. T., Flint,
H. J., et al. (2011). Recommendations for probiotic use-2011 update. J. Clin.
Gastroenterol. 45(Suppl.), S168–S171. doi: 10.1097/MCG.0b013e318230928b
Frank, D. N., St Amand, A. L., Feldman, R. A., Boedeker, E. C., Harpaz, N.,
and Pace, N. R. (2007). Molecular-phylogenetic characterization of microbial
community imbalances in human inflammatory bowel diseases. Proc. Natl.
Acad. Sci. U.S.A. 104, 13780–13785. doi: 10.1073/pnas.0706625104
Garrido-Mesa, J., Algieri, F., Rodriguez-Nogales, A., Utrilla, M. P., Rodriguez-
Cabezas, M. E., Zarzuelo, A., et al. (2015). A new therapeutic association
to manage relapsing experimental colitis: doxycycline plus Saccharomyces
boulardii. Pharmacol. Res. 97, 48–63. doi: 10.1016/j.phrs.2015.04.005
Garrido-Mesa, N., Utrilla, P., Comalada, M., Zorrilla, P., Garrido-Mesa, J.,
Zarzuelo, A., et al. (2011). The association of minocycline and the probiotic
Escherichia coli Nissle 1917 results in an additive beneficial effect in a DSS
model of reactivated colitis in mice. Biochem. Pharmacol. 82, 1891–1900.
doi: 10.1016/j.bcp.2011.09.004
Gersemann, M., Becker, S., Kubler, I., Koslowski, M., Wang, G., Herrlinger, K. R.,
et al. (2009). Differences in goblet cell differentiation between Crohn’s disease
and ulcerative colitis. Differentiation 77, 84–94. doi: 10.1016/j.diff.2008.09.008
Ghouri, Y. A., Richards, D. M., Rahimi, E. F., Krill, J. T., Jelinek, K. A., and
Dupont, A. W. (2014). Systematic review of randomized controlled trials of
probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin. Exp.
Gastroenterol. 7, 473–487. doi: 10.2147/CEG.S27530
Giahi, L., Aumueller, E., Elmadfa, I., and Haslberger, A. G. (2012). Regulation
of TLR4, p38 MAPkinase, IkappaB and miRNAs by inactivated strains of
lactobacilli in human dendritic cells. Benef. Microbes 3, 91–98. doi: 10.3920/
BM2011.0052
Grabig, A., Paclik, D., Guzy, C., Dankof, A., Baumgart, D. C., Erckenbrecht, J.,
et al. (2006). Escherichia coli strain Nissle 1917 ameliorates experimental colitis
via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect.
Immun. 74, 4075–4082. doi: 10.1128/IAI.01449-05
Hafez, M., Hayes, K., Goldrick, M., Grencis, R. K., and Roberts, I. S. (2010). The
K5 capsule of Escherichia coli strain Nissle 1917 is important in stimulating
expression of Toll-like receptor 5, CD14, MyD88, and TRIF together with the
induction of interleukin-8 expression via the mitogen-activated protein kinase
pathway in epithelial cells. Infect. Immun. 78, 2153–2162. doi: 10.1128/IAI.
01406-09
Haneklaus, M., Gerlic, M., Kurowska-Stolarska, M., Rainey, A. A., Pich, D.,
Mcinnes, I. B., et al. (2012). Cutting edge: miR-223 and EBV miR-BART15
regulate the NLRP3 inflammasome and IL-1beta production. J. Immunol. 189,
3795–3799. doi: 10.4049/jimmunol.1200312
Hartog, A., Belle, F. N., Bastiaans, J., De Graaff, P., Garssen, J., Harthoorn, L. F.,
et al. (2015). A potential role for regulatory T-cells in the amelioration of DSS
induced colitis by dietary non-digestible polysaccharides. J. Nutr. Biochem. 26,
227–233. doi: 10.1016/j.jnutbio.2014.10.011
Kim, Y. S., and Ho, S. B. (2010). Intestinal goblet cells and mucins in health and
disease: recent insights and progress. Curr. Gastroenterol. Rep. 12, 319–330.
doi: 10.1007/s11894-010-0131-2
Kim, Y. S., and Milner, J. A. (2007). Dietary modulation of colon cancer risk.
J. Nutr. 137, 2576S–2579S. doi: 10.1093/jn/137.11.2576S
Korzenik, J. R., and Podolsky, D. K. (2006). Evolving knowledge and therapy of
inflammatory bowel disease. Nat. Rev. Drug Discov. 5, 197–209. doi: 10.1038/
nrd1986
Frontiers in Pharmacology | www.frontiersin.org 11 May 2018 | Volume 9 | Article 468
fphar-09-00468 May 8, 2018 Time: 16:57 # 12
Rodríguez-Nogales et al. EcN Prevents DSS-Induced Dysbiosis
Kostic, A. D., Xavier, R. J., and Gevers, D. (2014). The microbiome in inflammatory
bowel disease: current status and the future ahead. Gastroenterology 146,
1489–1499. doi: 10.1053/j.gastro.2014.02.009
Kruis, W., Fric, P., Pokrotnieks, J., Lukas, M., Fixa, B., Kascak, M., et al. (2004).
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli
Nissle 1917 is as effective as with standard mesalazine. Gut 53, 1617–1623.
doi: 10.1136/gut.2003.037747
Lu, Z. J., Wu, J. J., Jiang, W. L., Xiao, J. H., Tao, K. Z., Ma, L., et al. (2017).
MicroRNA-155 promotes the pathogenesis of experimental colitis by repressing
SHIP-1 expression. World J. Gastroenterol. 23, 976–985. doi: 10.3748/wjg.v23.
i6.976
Mahler, M., Bristol, I. J., Leiter, E. H., Workman, A. E., Birkenmeier, E. H., Elson,
C. O., et al. (1998). Differential susceptibility of inbred mouse strains to dextran
sulfate sodium-induced colitis. Am. J. Physiol. 274, G544–G551. doi: 10.1152/
ajpgi.1998.274.3.G544
Manichanh, C., Rigottier-Gois, L., Bonnaud, E., Gloux, K., Pelletier, E., Frangeul, L.,
et al. (2006). Reduced diversity of faecal microbiota in Crohn’s disease revealed
by a metagenomic approach. Gut 55, 205–211. doi: 10.1136/gut.2005.073817
Mankertz, J., and Schulzke, J. D. (2007). Altered permeability in inflammatory
bowel disease: pathophysiology and clinical implications. Curr. Opin.
Gastroenterol. 23, 379–383. doi: 10.1097/MOG.0b013e32816aa392
McGuckin, M. A., Eri, R., Simms, L. A., Florin, T. H., and Radford-Smith, G.
(2009). Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm.
Bowel Dis. 15, 100–113. doi: 10.1002/ibd.20539
Meyer, F., Paarmann, D., D’souza, M., Olson, R., Glass, E. M., Kubal, M., et al.
(2008). The metagenomics RAST server - a public resource for the automatic
phylogenetic and functional analysis of metagenomes. BMC Bioinformatics
9:386. doi: 10.1186/1471-2105-9-386
O’Connell, R. M., Kahn, D., Gibson, W. S., Round, J. L., Scholz, R. L., Chaudhuri,
A. A., et al. (2010). MicroRNA-155 promotes autoimmune inflammation
by enhancing inflammatory T cell development. Immunity 33, 607–619.
doi: 10.1016/j.immuni.2010.09.009
O’Connell, R. M., Rao, D. S., and Baltimore, D. (2012). microRNA regulation
of inflammatory responses. Annu. Rev. Immunol. 30, 295–312. doi: 10.1146/
annurev-immunol-020711-075013
Parks, D. H., Tyson, G. W., Hugenholtz, P., and Beiko, R. G. (2014). STAMP:
statistical analysis of taxonomic and functional profiles. Bioinformatics 30,
3123–3124. doi: 10.1093/bioinformatics/btu494
Patel, R. M., and Lin, P. W. (2010). Developmental biology of gut-probiotic
interaction. Gut Microbes 1, 186–195. doi: 10.4161/gmic.1.3.12484
Persborn, M., and Soderholm, J. D. (2013). Commentary: the effects of
probiotics on barrier function and mucosal pouch microbiota during
maintenance treatment for severe pouchitis in patients with ulcerative colitis
- Authors’ reply. Aliment. Pharmacol. Ther. 38, 1406–1407. doi: 10.1111/apt.
12535
Power, S. E., O’toole, P. W., Stanton, C., Ross, R. P., and Fitzgerald, G. F. (2014).
Intestinal microbiota, diet and health. Br. J. Nutr. 111, 387–402. doi: 10.1017/
S0007114513002560
Prisciandaro, L., Geier, M., Butler, R., Cummins, A., and Howarth, G. (2009).
Probiotics and their derivatives as treatments for inflammatory bowel disease.
Inflamm. Bowel Dis. 15, 1906–1914. doi: 10.1002/ibd.20938
Rodriguez-Nogales, A., Algieri, F., Garrido-Mesa, J., Vezza, T., Utrilla, M. P.,
Chueca, N., et al. (2017). Differential intestinal anti-inflammatory effects of
Lactobacillus fermentum and Lactobacillus salivarius in DSS mouse colitis:
impact on microRNAs expression and microbiota composition. Mol. Nutr. Food
Res. 61:1700144. doi: 10.1002/mnfr.201700144
Sambrook, J., and Russell, D. W. (2006). Purification of nucleic acids by extraction
with phenol:chloroform. CSH Protoc. 2006:pdb.prot4455. doi: 10.1101/pdb.
prot4455
Sanchez de Medina, F., Galvez, J., Romero, J. A., and Zarzuelo, A. (1996). Effect
of quercitrin on acute and chronic experimental colitis in the rat. J. Pharmacol.
Exp. Ther. 278, 771–779.
Sanz, Y., and Moya-Perez, A. (2014). Microbiota, inflammation and obesity. Adv.
Exp. Med. Biol. 817, 291–317. doi: 10.1007/978-1-4939-0897-4_14
Schaefer, J. S., Montufar-Solis, D., Vigneswaran, N., and Klein, J. R. (2011). Selective
upregulation of microRNA expression in peripheral blood leukocytes in IL-
10-/- mice precedes expression in the colon. J. Immunol. 187, 5834–5841.
doi: 10.4049/jimmunol.1100922
Schultz, M., Strauch, U. G., Linde, H. J., Watzl, S., Obermeier, F., Gottl, C., et al.
(2004). Preventive effects of Escherichia coli strain Nissle 1917 on acute and
chronic intestinal inflammation in two different murine models of colitis. Clin.
Diagn. Lab. Immunol 11, 372–378. doi: 10.1128/CDLI.11.2.372-378.2004
Singh, S., Stroud, A. M., Holubar, S. D., Sandborn, W. J., and Pardi, D. S. (2015).
Treatment and prevention of pouchitis after ileal pouch-anal anastomosis
for chronic ulcerative colitis. Cochrane Database Syst. Rev. 11:CD001176.
doi:10.1002/14651858.CD001176.pub3
Singh, U. P., Murphy, A. E., Enos, R. T., Shamran, H. A., Singh, N. P., Guan, H.,
et al. (2014). miR-155 deficiency protects mice from experimental colitis
by reducing T helper type 1/type 17 responses. Immunology 143, 478–489.
doi: 10.1111/imm.12328
Souza, E. L., Elian, S. D., Paula, L. M., Garcia, C. C., Vieira, A. T., Teixeira,
M. M., et al. (2016). Escherichia coli strain Nissle 1917 ameliorates experimental
colitis by modulating intestinal permeability, the inflammatory response and
clinical signs in a faecal transplantation model. J. Med. Microbiol. 65, 201–210.
doi: 10.1099/jmm.0.000222
Starczynowski, D. T., Kuchenbauer, F., Argiropoulos, B., Sung, S., Morin, R.,
Muranyi, A., et al. (2010). Identification of miR-145 and miR-146a as mediators
of the 5q- syndrome phenotype. Nat. Med. 16, 49–58. doi: 10.1038/nm.2054
Stephani, J., Radulovic, K., and Niess, J. H. (2011). Gut microbiota, probiotics
and inflammatory bowel disease. Arch. Immunol. Ther. Exp. 59, 161–177.
doi: 10.1007/s00005-011-0122-5
Walker, A. W., Sanderson, J. D., Churcher, C., Parkes, G. C., Hudspith,
B. N., Rayment, N., et al. (2011). High-throughput clone library analysis of
the mucosa-associated microbiota reveals dysbiosis and differences between
inflamed and non-inflamed regions of the intestine in inflammatory bowel
disease. BMC Microbiol. 11:7. doi: 10.1186/1471-2180-11-7
Wang, Q., Garrity, G. M., Tiedje, J. M., and Cole, J. R. (2007). Naive Bayesian
classifier for rapid assignment of rRNA sequences into the new bacterial
taxonomy. Appl. Environ. Microbiol. 73, 5261–5267. doi: 10.1128/AEM.0
0062-07
Wehkamp, J., Harder, J., Wehkamp, K., Wehkamp-Von Meissner, B., Schlee, M.,
Enders, C., et al. (2004). NF-kappaB- and AP-1-mediated induction of human
beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917:
a novel effect of a probiotic bacterium. Infect. Immun. 72, 5750–5758.
doi: 10.1128/IAI.72.10.5750-5758.2004
Xu, J., Wu, C., Che, X., Wang, L., Yu, D., Zhang, T., et al. (2011). Circulating
microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular
carcinoma or chronic hepatitis. Mol. Carcinog. 50, 136–142. doi: 10.1002/mc.
20712
Xu, X. M., and Zhang, H. J. (2016). miRNAs as new molecular insights
into inflammatory bowel disease: crucial regulators in autoimmunity and
inflammation. World J. Gastroenterol. 22, 2206–2218. doi: 10.3748/wjg.v22.i7.
2206
Ye, D., Guo, S., Al-Sadi, R., and Ma, T. Y. (2011). MicroRNA regulation of intestinal
epithelial tight junction permeability. Gastroenterology 141, 1323–1333.
doi: 10.1053/j.gastro.2011.07.005
Zhang, Q., Wu, Y., Wang, J., Wu, G., Long, W., Xue, Z., et al. (2016). Accelerated
dysbiosis of gut microbiota during aggravation of DSS-induced colitis by a
butyrate-producing bacterium. Sci. Rep. 6:27572. doi: 10.1038/srep27572
Zhao, H., Zhu, L., Jin, Y., Ji, H., Yan, X., and Zhu, X. (2012). miR-375 is
highly expressed and possibly transactivated by achaete-scute complex homolog
1 in small-cell lung cancer cells. Acta Biochim. Biophys. Sin. 44, 177–182.
doi: 10.1093/abbs/gmr110
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Rodríguez-Nogales, Algieri, Garrido-Mesa, Vezza, Utrilla, Chueca,
Fernández-Caballero, García, Rodríguez-Cabezas and Gálvez. This is an open-access
article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pharmacology | www.frontiersin.org 12 May 2018 | Volume 9 | Article 468
